ACME Laboratories (DHA:ACMELAB) Cyclically Adjusted Revenue per Share: BDT126.94 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:ACMELAB ACME Laboratories Ltd DHA:ACMELAB
85 GF Score
Price BDT82.80
GF Value BDT126.24
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is ACME Laboratories Cyclically Adjusted Revenue per Share?

ACME Laboratories DHA:ACMELAB -0.84% 85 Cyclically Adjusted Revenue per Share is BDT126.94 as of Mar. 2026. GuruFocus rates DHA:ACMELAB with a GF Score™ of 85/100 and a GF Value™ of BDT126.24 (Possible Value Trap). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

ACME Laboratories's adjusted revenue per share for the three months ended in Mar. 2026 was BDT49.364. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is BDT126.94 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-25), ACME Laboratories's current stock price is BDT82.80. ACME Laboratories's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was BDT126.94. ACME Laboratories's Cyclically Adjusted PS Ratio of today is 0.65.

During the past 9 years, the highest Cyclically Adjusted PS Ratio of ACME Laboratories was 0.67. The lowest was 0.59. And the median was 0.61.


ACME Laboratories  (DHA:ACMELAB) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

ACME Laboratories's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=82.80/126.94
=0.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 9 years, the highest Cyclically Adjusted PS Ratio of ACME Laboratories was 0.67. The lowest was 0.59. And the median was 0.61.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


ACME Laboratories Cyclically Adjusted Revenue per Share Related Terms


ACME Laboratories Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for ACME Laboratories's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ACME Laboratories Cyclically Adjusted Revenue per Share Chart

ACME Laboratories Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

ACME Laboratories Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 121.66 126.94

DHA:ACMELAB vs ZTS, UTHR, VTRS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, ACME Laboratories's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ACME Laboratories Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ACME Laboratories's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where ACME Laboratories's Cyclically Adjusted PS Ratio falls into.


DHA:ACMELAB
85GF Score
ACME Laboratories Ltd DHA:ACMELAB
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ACME Laboratories Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ACME Laboratories's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=49.364/330.2130*330.2130
=49.364

Current CPI (Mar. 2026) = 330.2130.

ACME Laboratories Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201603 15.116 238.132 20.961
201606 16.956 241.018 23.231
201609 15.141 241.428 20.709
201612 15.519 241.432 21.226
201703 15.538 243.801 21.045
201706 17.957 244.955 24.207
201709 16.883 246.819 22.587
201712 17.339 246.524 23.225
201803 17.294 249.554 22.884
201806 18.489 251.989 24.228
201809 18.494 252.439 24.192
201812 19.163 251.233 25.187
201903 19.227 254.202 24.976
201906 20.162 256.143 25.992
201909 21.094 256.759 27.129
201912 22.003 256.974 28.274
202003 22.599 258.115 28.911
202006 24.143 257.797 30.925
202009 23.514 260.280 29.832
202012 23.706 260.474 30.053
202103 24.685 264.877 30.774
202106 26.169 271.696 31.805
202109 28.073 274.310 33.794
202112 26.849 278.802 31.800
202203 28.599 287.504 32.847
202206 29.267 296.311 32.616
202209 31.133 296.808 34.637
202212 30.745 296.797 34.207
202303 31.078 301.836 34.000
202306 34.363 305.109 37.190
202309 37.429 307.789 40.156
202312 35.995 306.746 38.749
202403 37.803 312.332 39.967
202406 39.659 314.175 41.684
202409 39.416 315.301 41.280
202412 41.422 315.605 43.339
202503 43.693 319.799 45.116
202509 46.717 324.800 47.496
202512 47.914 324.054 48.825
202603 49.364 330.213 49.364

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of BDT126.94 mean?
ACME Laboratories (DHA:ACMELAB) has a Cyclically Adjusted Revenue per Share of BDT126.94 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on ACME Laboratories and its competitors.
Is ACME Laboratories' Cyclically Adjusted Revenue per Share too high?
ACME Laboratories' current Cyclically Adjusted Revenue per Share is BDT126.94. Overall, ACME Laboratories has a GF Score™ of 85/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ACME Laboratories' Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
ACME Laboratories' Cyclically Adjusted Revenue per Share of BDT126.94 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on ACME Laboratories and its competitors. ACME Laboratories's current Cyclically Adjusted Revenue per Share is BDT126.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACME Laboratories stock overvalued right now?
Based on GuruFocus' analysis, ACME Laboratories (DHA:ACMELAB) is currently considered Possible Value Trap. The stock's GF Value™ is BDT126.24, compared to a current price of BDT82.80 — trading 34.4% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is BDT126.94. ACME Laboratories' overall GF Score™ is 85/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For ACME Laboratories (DHA:ACMELAB), the current Cyclically Adjusted Revenue per Share is BDT126.94 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ACME Laboratories (DHA:ACMELAB) Overvalued in 2026?

Based on GuruFocus' analysis, ACME Laboratories stock appears to be undervalued. The current stock price of BDT82.80 is trading 34.4% below its estimated GF Value™ of BDT126.24. GuruFocus considers ACME Laboratories to be Possible Value Trap.

Key valuation signals for DHA:ACMELAB:

  • Cyclically Adjusted Revenue per Share: BDT126.94
  • GF Value™: BDT126.24 vs. price of BDT82.80 (34.4% below fair value)
  • GF Score™: 85/100 with 8 warning signs

No single metric tells the full story. See the DHA:ACMELAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ACME Laboratories Business Description

Address 1/4, Kallayanpur, Mirpur Road, Court de la ACME, Dhaka, BGD, 1207
ACME Laboratories Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products in Bangladesh. The Company is engaged in manufacturing, marketing, and distribution of generic pharmaceuticals formulation products which includes human drugs comprising dosages form like a tablet, capsule, dry syrup, cream, ointment, powder, injection, dry powder inhaler, metered dosage inhaler, suppository, eye and nasal drop, liquid, liquid in hard gelatine, Blow Fill Seal (BFS) products, sachet products; veterinary drugs comprising dosages form like bolus, liquid,injection, water-soluble powder, premix and herbal drugs comprising dosages form like liquid, capsule, tablet, cream. The products of the company are sold in domestic and international markets.
85GF Score

Get the complete analysis for DHA:ACMELAB

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT82.80
Price
BDT126.24
GF Value